News
Positive profile for Enterome’s lymphoma candidate
Enterome – a company focused on immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases – has announces initial data from its pivotal phase 1/2 trial of EO2463.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Enterome – a company focused on immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases – has announces initial data from its pivotal phase 1/2 trial of EO2463.